Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults

In a phase 3 trial, adults (≥60 years of age) received one 120-μg dose of RSVpreF vaccine (17,215) or placebo (17,069). Vaccine efficacy against RSV-associated lower respiratory tract illness was 67 to 86%.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2023-04, Vol.388 (16), p.1465-1477
Hauptverfasser:	Walsh, Edward E., Pérez Marc, Gonzalo, Zareba, Agnieszka M., Falsey, Ann R., Jiang, Qin, Patton, Michael, Polack, Fernando P., Llapur, Conrado, Doreski, Pablo A., Ilangovan, Kumar, Rämet, Mika, Fukushima, Yasushi, Hussen, Nazreen, Bont, Louis J., Cardona, Jose, DeHaan, Elliot, Castillo Villa, Giselle, Ingilizova, Marinela, Eiras, Daniel, Mikati, Tarek, Shah, Rupal N., Schneider, Katherine, Cooper, David, Koury, Kenneth, Lino, Maria-Maddalena, Anderson, Annaliesa S., Jansen, Kathrin U., Swanson, Kena A., Gurtman, Alejandra, Gruber, William C., Schmoele-Thoma, Beate
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Aged Aging Aging General Antibodies, Viral Antigens Chronic illnesses Coronaviruses COVID-19 Double-Blind Method F protein Geriatrics Global Health Hepatitis Humans Immunization Infections Infectious Disease Infectious Disease General Influenza Injection Injections, Intramuscular Middle Aged Older people Placebos Respiratory diseases Respiratory syncytial virus Respiratory Syncytial Virus Infections - diagnosis Respiratory Syncytial Virus Infections - epidemiology Respiratory Syncytial Virus Infections - prevention & control Respiratory Syncytial Virus Vaccines - administration & dosage Respiratory Syncytial Virus Vaccines - adverse effects Respiratory Syncytial Virus Vaccines - therapeutic use Respiratory tract Respiratory Tract Infections - diagnosis Respiratory Tract Infections - epidemiology Respiratory Tract Infections - prevention & control Safety Seasons Treatment Outcome Vaccine Efficacy Vaccines Vaccines, Combined - administration & dosage Vaccines, Combined - adverse effects Vaccines, Combined - therapeutic use Viral Infections
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In a phase 3 trial, adults (≥60 years of age) received one 120-μg dose of RSVpreF vaccine (17,215) or placebo (17,069). Vaccine efficacy against RSV-associated lower respiratory tract illness was 67 to 86%.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2213836